Antibiotic Prophylaxis Before Shock Wave Lithotripsy
赞助:
Clinical Urology and Epidemiology Working Group
合作者:
信息的提供 (责任方):
Kari Tikkinen,Clinical Urology and Epidemiology Working Group
追踪信息 | |||
---|---|---|---|
首次提交日期 ICMJE | August 21, 2018 | ||
首次发布日期e ICMJE | October 2, 2018 | ||
最后更新发布日期 | October 2, 2018 | ||
预计研究开始日期 ICMJE | September 27, 2018 | ||
预计主要完成日期 | December 31, 2024 (主要结果测量的最终数据收集日期) | ||
目前主要观察指标 ICMJE |
Composite outcome including positive urine culture, symptoms of cystitis, pyelonephritis or urosepsis[ Time Frame: 7-14 days post-shockwave lithotripsy ] The composite outcome with be assessed as a dichotomous variable. The presence of Positive post-SWL urine culture (≥ 10e5 Colony Forming Unit/ ml), with one or more of symptoms of cystitis (defined as new onset burning sensation or pain with voiding, frequency, urgency), or pyelonephritis or urosepsis (hospital admission with fever ≥38.5 C) will be considered as an event. |
||
原始主要观察测量 ICMJE | 与当前相同 | ||
目前的二级观察 ICMJE |
|
||
描述性信息 | |||
简略标题 ICMJE | Antibiotic Prophylaxis Before Shock Wave Lithotripsy | ||
正式标题 ICMJE | A Multicenter Randomized Controlled Trial Assessing the Efficacy of Antimicrobial Prophylaxis for Extracorporeal Shock Wave Lithotripsy on Reducing Urinary Tract Infection | ||
简要概况 | This is a two arm, double blind RCT comparing the use of a single dose ciprofloxacin prior to SWL to saline alone. The multicenter trial will be conducted with a pragmatic emphasis including both high volume and low volume sites internationally. |
||
详细说明 | This is a two arm, double blind randomized controlled trial (RCT) comparing the use of a single dose ciprofloxacin prior to shock wave lithotripsy (SWL) to placebo. The multicenter trial will be conducted with a pragmatic emphasis including both high volume and low volume sites internationally. Eligibility criteria include patients older than 18 years presenting for SWL who do not meet one of the pre-defined exclusion criteria (outlined below). Eligible patients will provide written informed consent. Patients will undergo central randomization, which will be accessed by phone or internet. Un-blinding will occur only once statistical analysis is complete. Patients will undergo SWL using standard procedures at the participating center. Participants will asked to provide a pre-procedure study questionnaire, a modified International Prostate Symptom Score (IPSS) questionnaire and a urine sample for analysis prior to SWL and follow-up. Follow-up questionnaires and a requisition for urine culture will be provided in a pre-stamped, self-addressed envelope along with instructions to return both culture and questionnaires to their participating center at 7-14 days post-SWL. If the follow-up questionnaire has not been received by post-operative day 10 patients will receive a reminder phone call. A second envelope will be sent containing a requisition for urine culture and follow-up questionnaire when necessary. Alternatively, if a 2 week follow-up is conducted at the participating site then data-forms can be completed and collected at that time. In the event that a urine culture was not submitted 7 days post-operatively, one can be collected up to 14 days post-op. Additional clinical parameters such as presence of double J, stone characteristics and renal insufficiency will be recorded at the time of SWL by the dedicated research staff at the participating center. Data acquisition and occurrence of outcomes will be monitored continuously with scheduled audits. Primary and secondary outcomes are outlined below. The power calculation for this protocol was performed using Stata v.10.1 (StataCorp, College Station, TX). The investigators used the American Urological Association Best Practice Statement on antibiotic prophylaxis to estimate a 60% relative risk reduction with treatment arm. Therefore to achieve a power of 90% with a significance level of p<0.05, 661 patients will need to be recruited in each arm for a total of 1,322 patients. Accounting for 10% loss to follow-up, the total required will be 1454, or approximately 1500 patients. Assuming that 25% of patients screened will either refuse to be randomized or will meet one of the pre-defined exclusion criteria, a minimum of 2000 patients will need to be screened in order to randomize 1500 patients. | ||
研究类型 ICMJE | Interventional | ||
研究阶段 | Phase 4 | ||
研究设计 ICMJE | 分配: Randomized 干预模型: Parallel Assignment 干预模型描述: 盲法: Interventional 盲法描述:Patients will undergo central randomization, which will be accessed by phone or internet. Un-blinding will occur only once statistical analysis is complete. 主要目的: Prevention |
||
适用条件 ICMJE | |||
干预项目 ICMJE |
|
||
研究工具 |
|
||
招募信息 | |||
招募状态 ICMJE | Not yet recruiting | ||
预计入组 ICMJE |
1500 | ||
原始预计入组 ICMJE | 与当前相同 | ||
预计研究完成日期 | December 31, 2024 | ||
预计主要完成日期 | December 31, 2024 (主要结果测量的最终数据收集日期) | ||
合格标准 ICMJE | Inclusion Criteria: Patients older than 18 years presenting for SWL who do not meet one of the pre-defined exclusion criteria. Exclusion Criteria: - Pre-SWL urine analysis positive for nitrites - Pre-SWL urine culture reveals >10e5 Colony Forming Unit/ml of bacteria (positive urine culture) - Taking antibiotics for Urinary Tract Infection (UTI) or other cause - Suspected struvite stone (based on previous stone analysis, or partial staghorn) - Presence of nephrostomy tube - Requiring cystoscopy and ureteral stent insertion on the day of SWL - Presence of Foley catheter or patient on regular clean intermittent catheterization (CIC) - Presence of urinary diversion (ie: ileal conduit) - History of urosepsis prior to SWL - Known allergic reaction to trial antibiotic - Previous randomization in this trial - In the opinion of the independent treating urologist, it is not in the patient's best interest to participate | ||
性别 |
|
||
年龄 | 最小年龄:18 Years ,最大年龄:N/A | ||
接受健康的志愿者 | 没有 | ||
可入组国家 ICMJE | |||
管理信息 | 数据检测委员会 | ||
研究涉及美国FDA监管的产品 |
研究美国FDA监管的药品: No 研究涉及美国FDA监管的设备产品: No |
||
IPD 共享声明 |
|
||
责任方 | Kari Tikkinen,Clinical Urology and Epidemiology Working Group | ||
研究赞助商 ICMJE | Clinical Urology and Epidemiology Working Group | ||
合作者 ICMJE | |||
研究员 ICMJE |
|
||
PRS 账户 | Clinical Urology and Epidemiology Working Group | ||
验证日期 | August 2018 | ||
ICMJE 国际医学期刊编辑委员会和 世界卫生组织 ICTRP 要求的元素 |
请使用微信扫码报名